1. Introduction {#sec1}
===============

Down syndrome (DS), or trisomy 21, is caused by an extra copy of chromosome 21. The prevalence of Alzheimer\'s disease (AD) and dementia in the general population and in people with DS increases with age ([@bib11; @bib12]). In DS, the densities of senile plaques and neurofibrillary tangles increase with aging but can occur in people as young as 37 years ([@bib10]). Despite the pathologic changes, the age of onset (AOO) of dementia varies ([@bib15]), suggesting that factors other than trisomy of *APP* in DS are important.

The study of genetic roles in AD contributes to understanding dementia in DS. We have previously shown that in DS polymorphisms in *PICALM* and *APOE* are associated with AOO of dementia, and there is a nonsignificant trend in risk allele loading derived from AD meta-analysis ([@bib7]). Conversely, study of dementia in DS, particularly the role of trisomy in chromosome 21, allows us to understand mechanisms of AD. *APP* and *BACE2* are both located on chromosome 21. We previously showed that haplotypes in *BACE2* are associated with AD ([@bib13]). However, other studies suggested that *BACE2* might not play a significant role in AD ([@bib3; @bib5]). We attempted to look into the role of *BACE2* in AOO of dementia in DS.

2. Methods {#sec2}
==========

The cohort, genotyping and quality control measures were as previously reported ([@bib7]). In brief, this comprised of 94 samples from 2 clinical trials (DOWNSLIT \[<http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=5927>\] and MEADOWS; [@bib4]) and 64 brain samples from various brain banks (details in [Supplementary Data](#appsec1){ref-type="sec"}). For samples from clinical trials, AOO of dementia was as recorded by the trial psychiatrist. Mean duration of dementia before death in people with DS is approximately 5 years, and AOO for the autopsy cohort was defined as the age of death minus 5, which assumes all individuals over the age of 34 years had dementia before death.

DNA was obtained from blood or brain using the commercially available DNeasy Blood and Tissue kit (Qiagen, UK). Genotyping was done in the UCL Genomics Centre using HumanOmniExpress-12v1_H beadchips. After the initial quality control check, 129 samples remained (males: 72; females: 57). Of these, only 70 samples were classified as having dementia and only 67 samples were AOO documented. This formed the cohort for current analysis and was as previously reported ([@bib7]) (details in [Supplementary Table 1](#appsec1){ref-type="sec"}).

Clustering of genotypes for autosomal chromosomes in GenomeStudio (Illumina, San Diego, CA, USA) is based on diploid status. Manual recluster for polyploidy-genotyping was performed using GenomeStudio module v1.9.4 (<http://res.illumina.com/documents/products/technotes/technote_genomestudio_polyploid_genotyping.pdf>). All single-nucleotide polymorphisms (SNPs) (n = 85) within the *BACE2* locus +/− 50 kb were reclustered and the genotypes of SNPs were exported for further analysis. The minor allele was evaluated to be the risk allele.

Regression analysis was performed in R v2.15.2 ([@bib17]). AOO regression was analyzed using an additive model. Components 1 and 2 in PLINK, multidimensional scaling ([@bib16]) were used as covariates, in addition to gender and the classification of the sample as clinical or autopsy. A nominal *p* value of 0.05 was used as a cutoff for nominal significance.

3. Results {#sec3}
==========

The 67 cases (men:women = 36:31) had average age of 55.6 years (standard deviation ± 7.3). There was a total of 85 SNPs within 50 kb of *BACE2* (chr21:42539728--42654461, hg19). Of these, 2 SNPs were excluded because they were monomorphic ([Supplementary Table 1](#appsec1){ref-type="sec"}).

Among the 83 SNPs, 6 SNPs have a nominal significance with *p* \< 0.05 and another 8 SNPs have *p* value between 0.05 and 0.1 ([Fig. 1](#fig1){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}, and [Supplementary Table 1](#appsec1){ref-type="sec"}). All except 4 SNPs were clustered within the exons 6--9 and the 3′ region ([Supplementary Fig. 1](#appsec1){ref-type="sec"}), which fell within a haplotype block of Hapmap3 European cohort ([Supplementary Fig. 2](#appsec1){ref-type="sec"}). The most significant SNP, rs7287133 is in linkage disequilibrium (LD) with some other significant SNPs and borderline significant SNPs ([Supplementary Fig. 1](#appsec1){ref-type="sec"}), suggesting that the haplotype in this region is probably important for AD.

4. Discussion {#sec4}
=============

There are 2 major limitations in the present study. The first one is the small sample size and therefore limits the power to conclude definitely the association. The second one comes from correction for multiple testing. Multiple testing is performed for all SNPs within *BACE2*.

Correction for multiple testing within high LD block can be difficult. Applying Bonferroni correction is too conservative and leads to false negative results. HapMap Utah residents (Centre d′Etude du Polymorphisme Humain) with Northern and Western European ancestry and Toscani in Italy (CEU + TSI) data suggest the *BACE2* region falls into 5 major blocks ([Supplementary Fig. 2](#appsec1){ref-type="sec"}). Most of the nominal and borderline significant SNPs cluster around the exon 6 to the 3′ untranslated region (3′UTR), and Hapmap data suggest that this is a block of high LD. If we apply the correction according to the number of haplotype blocks, the corrected *p* value of significance should be 0.05/5 = 0.01. Our SNPs will fall out of significance but are still borderline significant.

Another theoretical correction has to be made for testing multiple genes. Our previous report suggested *PICALM* and *APOE* as risk factors for early onset of dementia in DS ([@bib7]). In the previous study, we tested 157 SNPs in 74 gene regions (35 SNPs in 15 genes are among the *APOE* block). The present study is focused on *BACE2* with the genotype manual reclustered for trisomy as mentioned in section [2](#sec2){ref-type="sec"}, and can be viewed as a complimentary study to previous study. Straight multiple testing correction will result in the currently studied SNPs becoming insignificant.

The current data on DS support our group\'s previous report ([@bib13]) of association of haplotypes in *BACE2* with AD. In a study by Myllykangas, we found rs2252576 (minor T allele) and haplotypes including this SNP were associated with AD in Finns and Americans. Our current AOO regression data also show that rs2252576-T allele possibly associates with an earlier age of onset of dementia (slope = −2.4 year/per T allele) in DS.

The role of *BACE2* in AD has been controversial. *BACE2* expression was not found to be increased in adult DS brain ([@bib3]). However, [@bib9] found increased *BACE2* expression in adult DS brain. [@bib5] reported an increase in *BACE2* messenger RNA in DS that did not translate into increased *BACE2* protein levels and activities in DS, despite increases in other neurodegenerative diseases. However, overexpression of *BACE2* was found to decrease amyloid beta production in neuronal cultures ([@bib1; @bib18]).

Our SNPs with nominal and borderline significance were observed mainly around the 3′ end and not in the 5′UTR region. This is in congruent with a negative association of SNPs in 5′-flanking region done in an Asian population of AD ([@bib19]).

Association of SNPs in *BACE2* with AD is not found in the recent mega meta-analyses of genome-wide association study ([@bib6; @bib8; @bib14]). The discrepancy may be related to our study population being all trisomy 21, including *APP*.

We postulate that with duplication of *APP*, the increased gene dosage contributes a greater role in the pathogenesis of AD, compared with other AD cases without *APP* duplication. Subsequently, gene products, for example from *BACE2*, that interact with the *APP* will play a greater role in dementia pathogenesis among trisomy cases than in AD subjects with diploid *APP*. Expression of *BACE2* was reported to be increased in adult brain with DS ([@bib9]). The upregulation of the *APP*-related system in DS may explain why *BACE2* SNPs are not found to be associated in general AD genome-wide association study, but are suggestive when the dementia cohort is made up of *APP* trisomy, as in the present study.

Our data on rs2252576, rs2837990, and rs7281733 suggest that the minor alleles may predispose to early onset of dementia, implying these variants and the functional alteration caused are pathogenic. The opposite was found with rs7510366 and rs6517664. Pathogenicity can be because of variants enhancing a pathogenic role of the protein or diminishing a protective role. Hence, other studies are needed to determine the functional role of *BACE2*.

In summary, we find variants in *BACE2* that possibly affect the AOO of dementia in DS, suggesting a potential role of *BACE2* in AD and DS. Dementia in DS can provide an important model to study the role of *APP* and related genes in AD.
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![Plot of 6 SNPs with significant association with AOO around *BACE2*. Median age of onset of dementia according to genotype. 0 = homozygous major allele, 1 = 2 major alleles and 1 minor allele, 2 = 1 major allele and 2 minor alleles, and 3 = homozygous trisomy of minor allele. (A) rs9981478 C/T (minor/major); (B) rs7510366 T/C; (C) rs2252576 T/C; (D) rs2837990 A/G; (E) rs7281733 A/G; and (F) rs6517664 T/C. Abbreviations: AOO, age of onset; SNP, single-nucleotide polymorphism.](gr1){#fig1}

###### 

SNPs with significant association with AOO around *BACE2*

                           SNP         Position   Minor allele   Nominal *p* value
  ------------------------ ----------- ---------- -------------- -------------------
  Nominal significant      rs9981478   42558694   C              0.0316
  rs7510366                42581927    T          0.0274         
  rs2252576                42615293    T          0.0315         
  rs2837990                42620149    A          0.0394         
  rs7281733                42655515    A          0.0258         
  rs6517664                42704983    T          0.0376         
  Borderline significant   rs6517656   42583738   A              0.0866
  rs2837994                42624124    A          0.091          
  rs11702001               42627969    A          0.0722         
  rs8133778                42642038    A          0.075          
  rs2838003                42649357    C          0.0774         
  rs2006737                42657187    G          0.0793         
  rs1072869                42657548    C          0.0607         
  rs9984207                42662259    T          0.0601         

Key: AOO, age of onset; SNP, single-nucleotide polymorphism.
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